Articles related to VALVULAR HEART DISEASE (VHD)

Patients with primary tricuspid regurgitation had longer survival than those with secondary or lead-associated TR in a 12,899-patient Mayo Clinic retrospective cohort.

Registry data shows that comorbidities not captured in traditional surgical risk scores, particularly atrial fibrillation and poor baseline functional status, significantly impact post-TAVR outcomes in low-risk patients.

DETECT AS trial showed electronic notifications increased AVR rates by 11% overall and 14% in symptomatic patients, while EARLY TAVR analyses confirmed superior outcomes with timely intervention versus surveillance, with biomarkers failing to predict optimal treatment timing.

The bRIGHT study demonstrates that T-TEER using the TriClip system can lead to sustained TR reduction and quality of life improvements in a diverse, real-world population with advanced tricuspid valve disease.

The FDA has recalled Abbott’s HeartMate 3 LVAD after reports of severe complications during implantation, including blood leakage and air entry, which can lead to serious surgical risks.

A 75-year-old man with dyspnea and exertional syncope is diagnosed with aortic stenosis. After an echocardiogram, what’s next?